UNASSIGNED: Metabolism has been a heavily investigated topic in @entity5 research for the past decade. Although the role of aerobic glycolysis (the Warburg effect) in @entity5 has been extensively studied, abnormalities in other metabolic pathways are only just being understood in @entity5 . One such pathway is glycogen metabolism; its involvement in @entity5 development, particularly in @entity5 , and possible ways of exploiting aberrations in this process for treatment are currently being studied. New research shows that the glycogen debranching enzyme amylo-a-1,6-glucosidase, @entity32404 ( @entity32404 ) is a novel @entity5 suppressor in @entity150 . Loss of @entity32404 leads to rapid proliferation of @entity150 cells. Another enzyme involved in glycogen debranching, glycogen phosphorylase, has been shown to be a @entity5 promoter in @entity5 , including in @entity263 . Studies demonstrate that @entity150 cells in which @entity32404 expression is lost are more metabolically active than cells with intact @entity32404 expression, and these cells are more sensitive to inhibition of both glycolysis and @entity8959 synthesis-two targetable pathways. As a @entity5 promoter and enzyme, glycogen phosphorylase can be directly targeted, and preclinical inhibitor studies are promising. However, few of these glycogen phosphorylase inhibitors have been tested for @entity5 treatment in the clinical setting. Several possible limitations to the targeting of @entity32404 and glycogen phosphorylase might also exist.

Targeting glycogen metabolism in XXXX .

@entity8959 :: ('D005998', 'Chemical') :: ['glycine'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urothelial malignancies', 'cancer', 'tumour'] @entity32404 :: ('178', 'Gene') :: ['AGL', '4-a-glucanotransferase'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']
@entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']
